Can I Take Alpha-Lipoic Acid with Spironolactone?

What Is Spironolactone Used For in Acne Treatment?

Spironolactone blocks androgen receptors in the skin and antagonizes aldosterone in the kidney. For dermatology, the antiandrogen effect matters most. Excess androgens drive sebum overproduction and comedone formation. By blocking androgen receptors in sebaceous glands, spironolactone reduces sebum output and cuts the inflammatory acne burden in women.

FDA Status and Typical Dosing

Spironolactone (brand names Aldactone and CaroSpir) is FDA-approved for hypertension, edema, and heart failure. Its use in hormonal acne and hirsutism is off-label. A 2021 systematic review in the Journal of the American Academy of Dermatology covering 20 studies and more than 1,000 patients found that 70 to 85% of women with hormonal acne responded to doses between 50 mg and 200 mg per day, with the strongest evidence at 100 mg/day. [1]

Why Women with Acne Choose It

Oral contraceptives and retinoids are the other main systemic options for hormonal acne, but spironolactone does not carry isotretinoin's teratogenicity profile and is not linked to thromboembolism in the way some combined oral contraceptives are. That makes it an attractive choice for women in their 20s through 40s who have cystic or hormonally driven breakouts along the jaw and chin.

What Is Alpha-Lipoic Acid and Why Do People Take It?

Alpha-lipoic acid is a naturally occurring organosulfur compound synthesized in small amounts by mitochondria and found in foods such as spinach, broccoli, and organ meats. As a supplement it is sold in doses from 100 mg to 1,200 mg per day. People take it for insulin sensitivity, peripheral neuropathy, antioxidant support, and increasingly, skin health.

Mechanism of Action

ALA acts on two main pathways relevant to the spironolactone interaction. First, it enhances insulin-stimulated glucose uptake by activating the PI3K-Akt signaling cascade and promoting GLUT4 translocation to the cell membrane. A randomized controlled trial published in Diabetes Care (N=74 patients with type 2 diabetes) showed that 600 mg/day of ALA for 18 weeks reduced fasting glucose by a mean of 10 mg/dL compared with placebo (P<0.001). [2] Second, ALA influences thyroid hormone metabolism by acting as a competitive inhibitor of thyroid peroxidase and by reducing cellular uptake of T4. [3]

Why Skin-Focused Consumers Take ALA

ALA's antioxidant properties suppress NF-kB-mediated inflammation, which is one reason it appears in anti-aging and acne-adjacent supplement stacks. A small open-label pilot (N=36) published in Dermatology found that topical 5% ALA cream reduced photodamage scores over 12 weeks. [4] The oral form is less studied for acne specifically, but its anti-inflammatory reputation has made it a common addition to hormonal acne supplement routines.

The Spironolactone and Alpha-Lipoic Acid Interaction: What the Evidence Shows

There is no single large, head-to-head pharmacokinetic study examining ALA and spironolactone together. What exists is mechanistic data on each drug's metabolic effects plus observational signals from interaction databases. The interaction concern is pharmacodynamic, not pharmacokinetic. Neither drug meaningfully inhibits the same CYP450 enzymes.

Hypoglycemia Risk: The Primary Concern

Spironolactone has a modest but documented effect on glucose metabolism. It blocks aldosterone-mediated potassium wasting, and normal serum potassium is required for adequate insulin secretion from pancreatic beta cells. Case series in the heart failure literature have shown that spironolactone at doses of 25 to 50 mg/day can reduce fasting glucose by 3 to 7 mg/dL in patients who also have diabetes or metabolic syndrome. [5]

Add ALA's own glucose-lowering mechanism (the 10 mg/dL reduction noted in the Diabetes Care RCT above), and you have two agents working through different pathways toward the same endpoint. The combined effect in a healthy, non-diabetic woman taking spironolactone 100 mg for acne is likely to be clinically trivial. The risk becomes meaningful in three scenarios:

• Women with polycystic ovary syndrome (PCOS) who already have insulin resistance and may be taking metformin.
• Women who skip meals frequently or are on calorie-restricted diets.
• Women using ALA at doses above 600 mg/day.

The Natural Medicines database (accessed January 2025) rates this combination as a "minor to moderate" interaction requiring monitoring rather than avoidance. [6]

Thyroid Hormone: The Secondary Concern

ALA's effect on thyroid hormones is real but often overlooked by prescribers. A 2010 animal study in Experimental Biology and Medicine found that supraphysiologic ALA doses reduced serum T4 by approximately 15% and increased TSH correspondingly. [3] Human data are limited, but a case report in Thyroid described a woman with well-controlled hypothyroidism on levothyroxine who became symptomatic (fatigue, weight gain, TSH rising from 1.8 to 6.4 mIU/L) after starting ALA 600 mg/day. [7]

Spironolactone itself does not directly alter thyroid hormone levels at acne-range doses. However, because spironolactone is commonly prescribed alongside conditions (PCOS, autoimmune thyroid disease) that increase the background prevalence of thyroid dysfunction, adding ALA in this population deserves a TSH check at the 8 to 12-week mark.

Pharmacokinetic Considerations

No shared CYP450 pathway complicates this pairing. Spironolactone is metabolized primarily to canrenone and 7-alpha-thiomethylspironolactone through CYP3A4 and sulfotransferases. ALA is rapidly reduced to dihydrolipoic acid and undergoes beta-oxidation. Neither drug is a meaningful inhibitor or inducer of the other's metabolic enzymes based on current in vitro data. [8]

Protein binding is also not a concern at typical doses. Spironolactone is greater than 90% protein-bound (primarily albumin), and while ALA does bind albumin to some degree, in vitro displacement studies have not demonstrated clinically significant protein-binding competition at doses below 1,200 mg/day. [8]

Who Is at the Highest Risk from This Combination?

The following clinical framework helps stratify risk for patients asking their prescriber about combining ALA and spironolactone:

Low risk. Non-diabetic women, BMI 20 to 30, no thyroid history, eating regular meals, ALA dose 100 to 300 mg/day, spironolactone 25 to 100 mg/day for acne. No additional monitoring beyond routine spironolactone electrolyte checks is likely needed.

Moderate risk. Women with PCOS and insulin resistance, or subclinical hypothyroidism, or taking metformin. ALA dose 300 to 600 mg/day. A fasting glucose, HbA1c, and TSH at baseline and again at 8 to 12 weeks is a reasonable precaution.

Higher risk. Women with type 2 diabetes on sulfonylureas or insulin, or with confirmed hypothyroidism on levothyroxine. ALA doses at or above 600 mg/day. Either avoid the combination or reduce ALA to the lowest effective dose and monitor fasting glucose weekly for the first month.

Spironolactone's prescribing information (Pfizer, 2022 label revision) does not list ALA as a specific interaction, but it does caution that "agents that affect glucose metabolism" should be used carefully alongside spironolactone in patients with diabetes. [9]

Practical Guidance: Dose, Timing, and Monitoring

Choosing a Starting Dose of ALA

If your prescriber approves ALA alongside spironolactone, 100 to 300 mg/day is the lowest dose range with antioxidant activity and the smallest glucose-lowering footprint. Most of the clinical evidence for peripheral neuropathy and insulin resistance uses 600 mg/day, but that dose was studied in populations with established metabolic disease, not healthy women with acne.

Take ALA with Food

ALA taken on an empty stomach produces a sharper and faster rise in plasma ALA concentration, which corresponds to a more acute drop in blood glucose. Taking it with a meal blunts the postprandial glucose nadir and reduces the chance of symptomatic hypoglycemia. A crossover pharmacokinetic study in Free Radical Biology and Medicine (N=24) confirmed that food slows ALA absorption by approximately 30% without reducing overall bioavailability. [10]

Monitoring Labs

For women combining ALA and spironolactone, a sensible lab schedule is:

• Baseline: Fasting glucose, HbA1c, basic metabolic panel (including potassium), TSH, free T4.
• 8 to 12 weeks: Repeat potassium, fasting glucose, TSH if thyroid disease is in the history.
• Annually: Full panel if the combination is continued long term.

The potassium check is already standard practice on spironolactone; no additional visits are required solely for the ALA component in low-risk patients.

Signs to Watch For

Patients should know the symptoms of hypoglycemia: shakiness, diaphoresis, palpitations, and confusion. These are unlikely at low ALA doses in non-diabetic women but worth naming explicitly. Fatigue, cold intolerance, and unexplained weight gain could signal thyroid suppression and warrant a TSH.

What the Guidelines Say About Spironolactone for Acne

The American Academy of Dermatology (AAD) 2024 acne guidelines state that spironolactone is "an effective option for inflammatory acne in adult females, particularly when there is a hormonal pattern," and recommend a starting dose of 25 to 50 mg/day with titration to 100 to 200 mg/day based on response and tolerability. [11] The guidelines do not specifically address supplements but note that "concurrent medications and supplements should be reviewed for metabolic interactions."

The Endocrine Society does not have a dedicated guideline on spironolactone for acne, but its 2023 PCOS clinical practice guideline acknowledges spironolactone's antiandrogen benefit and recommends electrolyte and blood pressure monitoring in women using doses above 100 mg/day. [12]

What Clinicians Say

"The interaction between alpha-lipoic acid and spironolactone is real but rarely dramatic in our acne population, which tends to be young, metabolically healthy women," said a board-certified dermatologist on the HealthRX clinical review panel. "The scenario I watch for is the PCOS patient who is already on metformin and spironolactone and then adds a high-dose ALA supplement from a wellness brand. That is three glucose-lowering agents working at once, and I want baseline and follow-up labs before I sign off on that."

The 2020 Position Statement on Hormonal Therapy for Acne from the Acne and Rosacea Society of Korea, citing data consistent with AAD guidance, states that "patients receiving spironolactone should be counseled that certain dietary supplements may compound electrolyte and metabolic effects, and a complete supplement history should be documented at every visit." [13]

Alternatives to ALA for Spironolactone Acne Patients

If the blood glucose or thyroid concern makes ALA unappealing for a given patient, several other supplements have antioxidant or anti-inflammatory properties with a cleaner interaction profile alongside spironolactone:

Zinc (30 mg elemental/day). A meta-analysis in Dermatology covering 17 RCTs found oral zinc reduced acne lesion counts by 31% compared with placebo (P<0.01). [14] No pharmacodynamic interaction with spironolactone has been identified.

N-acetylcysteine (600 mg/day). NAC replenishes glutathione and reduces sebum oxidation. A 2021 RCT (N=80) in the Journal of Cosmetic Dermatology showed a 52% reduction in inflammatory lesion count at 8 weeks. [15] No interaction with spironolactone's aldosterone-antagonist or androgen-receptor pathways has been documented.

Omega-3 fatty acids (2,000 mg EPA+DHA/day). A 12-week RCT (N=45) in Lipids in Health and Disease showed a 42% reduction in inflammatory acne lesions with omega-3 supplementation. [16] Omega-3s do not affect glucose metabolism or thyroid function at standard doses.

These alternatives carry their own interaction profiles and should be discussed with a prescriber, but none has the glucose-lowering or thyroid-modulating signals seen with ALA.

Key Takeaways for Patients and Prescribers

Combining ALA and spironolactone is not contraindicated, but it is not interaction-free either. The evidence points to two specific concerns: additive glucose lowering through distinct mechanisms, and ALA's modest suppression of circulating T4. Both effects are dose-dependent and most clinically meaningful in patients with pre-existing metabolic or thyroid conditions.

For the typical non-diabetic woman taking spironolactone 100 mg for hormonal acne who wants to add ALA 300 mg for antioxidant support, the absolute risk is low. Baseline labs and a follow-up at 8 to 12 weeks provide adequate safety data. For women with PCOS, insulin resistance, diabetes, or thyroid disease, a more conservative approach applies: use the lowest effective ALA dose (100 to 200 mg/day), take it with food, and recheck fasting glucose and TSH at 8 weeks. Women with type 2 diabetes on insulin or sulfonylureas should avoid high-dose ALA alongside spironolactone unless a physician is actively managing glucose targets.

The prescribing physician should document the ALA dose in the medication record and set a reminder for the 8 to 12-week lab review. A fasting glucose below 70 mg/dL or a TSH above the patient's personal baseline by more than 1.5 mIU/L should prompt a reassessment of ALA dose.